Aug 23, 2021
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis Promotional launch of KORSUVA™ injection in the U.S. is expected in Q1 2022, with reimbursement in H1 2022 Company to host conference call today
Additional Formats
Aug 09, 2021
– New Drug Application (NDA) Filing for KORSUVA™ Injection in CKD-aP under Priority Review by U.S. Food and Drug Administration (FDA); PDUFA Target Action Date August 23, 2021 – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn. , Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.
Additional Formats
Apr 29, 2021
        – Study did not meet Primary Endpoint of worst-itch NRS change from baseline at         week 12 or Secondary Endpoint of 4-point responder analysis in the ITT patient population         – Study achieved Primary Endpoint of worst-itch NRS change and Secondary Endpoint of 4-point responder
Additional Formats
Displaying 1 - 10 of 16
Contact IR
email alerts